EVE Health Group Limited
Research EVE Health Group Limited (EVE) on Bullrun: market cap AUD 5.28M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerEVE
- ExchangeAU
- CountryAustralia
- SectorConsumer Defensive
- IndustryPackaged Foods
- CurrencyAUD
- Market capAUD 5.28M
- Financial periodFY2025
- RevenueAUD 1.73M
- Revenue growth-18.7%
- Net income-AUD 1.58M
- Free cash flow-AUD 1.62M
- Gross margin47.5%
Valuation Snapshot
latest market cap is AUD 5.28M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | AUD 1.73M | -AUD 1.58M | -AUD 1.62M | 47.5% | -0.01 | AUD 903.42K | AUD 91.29K | AUD 3.55M |
| FY2024 | AUD 2.13M | -AUD 1.90M | -AUD 1.11M | 41.1% | -0.02 | AUD 106.17K | AUD 74.85K | AUD 1.22M |
| FY2023 | AUD 2.33M | -AUD 3.07M | -AUD 1.65M | 35.5% | -0.02 | AUD 192.48K | AUD 514.95K | AUD 4.10M |
| FY2022 | AUD 2.39M | -AUD 5.37M | -AUD 3.80M | 40.8% | -0.05 | AUD 1.10M | AUD 492.39K | AUD 6.93M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-24 | AUD 5.28M | n/a | n/a | n/a |
About EVE Health Group Limited
EVE Health Group Limited, together with its subsidiaries, engages in the development, retail, and commercialization of health and wellness, and pharmaceutical products. The company lead product is Dyspro, a proprietary pharmaceutical-grade formulation to address dysmenorrhea (menstrual pain); and Libbo, a proprietary pharmaceutical-grade oral dissolving film formulation for the treatment of erectile dysfunction.
Related stock research
Other Consumer Defensive stocks
Frequently asked questions
What is EVE Health Group Limited's market cap?
EVE Health Group Limited's market capitalization is AUD 5.28M.
What does EVE Health Group Limited do?
EVE Health Group Limited, together with its subsidiaries, engages in the development, retail, and commercialization of health and wellness, and pharmaceutical products. The company lead product is Dyspro, a proprietary pharmaceutical-grade formulation to address dysmenorrhea (menstrual pain); and Libbo, a proprietary pharmaceutical-grade oral dissolving film formulation for the treatment of erectile dysfunction. It also offers Lactobacillus rhamnosus Beebiotic MAP01, a proprietary strain to support digestive health and vitality. The company was formerly known as EVE Investments Limited.